Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
UBS
Teva
Queensland Health
Medtronic
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca
Mallinckrodt

Generated: May 28, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,414,016

« Back to Dashboard

Which drugs does patent 6,414,016 protect, and when does it expire?

Patent 6,414,016 protects AMITIZA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-four countries.
Summary for Patent: 6,414,016
Title: Anti-constipation composition
Abstract:An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): ##STR1## where X.sub.1 and X.sub.2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
Inventor(s): Ueno; Ryuji (Potomac, MD)
Assignee: Sucampo, A.G. (Zurich, GH)
Application Number:09/655,760
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,414,016
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 6,414,016

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME ➤ Sign Up
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION ➤ Sign Up
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,414,016

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,114,890 Anti-constipation composition ➤ Sign Up
6,610,732 Anti-constipation composition ➤ Sign Up
8,748,454 Anti-constipation composition ➤ Sign Up
8,071,613 Anti-constipation composition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Healthtrust
Federal Trade Commission
Covington
Medtronic
Argus Health
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.